Feng Xu

Publications80
h-index16
Citations737
Highly Influential Citations37
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • Xiao Li
  • 167 Publications • 1,271 Citations
  • Chun-kang Chang
  • 184 Publications • 1,367 Citations
  • H. Kantarjian
  • 4,838 Publications • 221,792 Citations
  • Qi He
  • 79 Publications • 702 Citations
  • Publications
  • Influence
Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes
TLDR
It is suggested that mutations in epigenetic modification and splicesome genes are common in Chinese patients with MDS, while mutations in U2AF1 and SRSF2 appear to predict an unfavorable prognosis.
Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes
TLDR
A role for miR 10a/10b in the regulation of apoptosis in myelodysplastic syndrome is supported and the TWIST-1/miR10a/b-axis is suggested as a therapeutic target in myELodys Plastic syndrome.
Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome
TLDR
The results of this study show that mesenchymal stromal cells from patients with myelodysplastic syndrome are prone to senescence and that Dicer1 down-regulation promotes cellular senescences and decreases the differentiation and stem cell-supporting capacities of mesenchyal stromaal cells.
Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes
TLDR
A novel contribution of ROBO mutations to the pathogenesis of MDS is demonstrated and a key role for ROBO-SLIT2 signalling in MDS disease progression is highlighted.
Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.
TLDR
Decitabine may have a broad range of therapeutic applications when it is used in association with active adaptive immunity responses against up-regulated CTAs and T lymphocyte function in patients with myelodysplastic syndromes.
Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring
TLDR
Excessive overexpression of the EZH2, RING1, and BMI1 genes is common in MDS and indicate poor prognosis, as well as the relationship between the expression of PcG genes and epigenetic alteration and prognosis-risk scoring, which is explored for the first time.
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine
TLDR
The over-expression of RPL23 might confer apoptosis resistance in CD34+ cells, which may lead to disease progression and adverse prognosis in MDS.
SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome
TLDR
Findings suggest genomic loss of EZH2 contributes to overexpression of the HOX gene clusters in MDS through epigenetic modifications through methylation and demethylating modifications.
TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromes
TLDR
TP53 mutations might predict decitabine‐induced complete responses in patients with MDS, and DAC‐induced responses may result from partial suppression of malignant clones containing mutated TP53 genes.
...
1
2
3
4
5
...